Multi-omic features of oesophageal adenocarcinoma in patients treated with preoperative neoadjuvant therapy.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
31 05 2023
Historique:
received: 25 08 2021
accepted: 19 05 2023
medline: 2 6 2023
pubmed: 1 6 2023
entrez: 31 5 2023
Statut: epublish

Résumé

Oesophageal adenocarcinoma is a poor prognosis cancer and the molecular features underpinning response to treatment remain unclear. We investigate whole genome, transcriptomic and methylation data from 115 oesophageal adenocarcinoma patients mostly from the DOCTOR phase II clinical trial (Australian New Zealand Clinical Trials Registry-ACTRN12609000665235), with exploratory analysis pre-specified in the study protocol of the trial. We report genomic features associated with poorer overall survival, such as the APOBEC mutational and RS3-like rearrangement signatures. We also show that positron emission tomography non-responders have more sub-clonal genomic copy number alterations. Transcriptomic analysis categorises patients into four immune clusters correlated with survival. The immune suppressed cluster is associated with worse survival, enriched with myeloid-derived cells, and an epithelial-mesenchymal transition signature. The immune hot cluster is associated with better survival, enriched with lymphocytes, myeloid-derived cells, and an immune signature including CCL5, CD8A, and NKG7. The immune clusters highlight patients who may respond to immunotherapy and thus may guide future clinical trials.

Identifiants

pubmed: 37258531
doi: 10.1038/s41467-023-38891-x
pii: 10.1038/s41467-023-38891-x
pmc: PMC10232490
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3155

Informations de copyright

© 2023. The Author(s).

Références

J Clin Oncol. 2009 Oct 20;27(30):5062-7
pubmed: 19770374
Sci Rep. 2020 Sep 3;10(1):14514
pubmed: 32884042
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Oncoimmunology. 2021 Aug 4;10(1):1954807
pubmed: 34377591
Cell. 2018 Dec 13;175(7):1972-1988.e16
pubmed: 30550791
Genome Med. 2022 Jan 10;14(1):3
pubmed: 35012638
Bioinformatics. 2013 Jan 15;29(2):189-96
pubmed: 23175756
Nature. 2017 Mar 2;543(7643):65-71
pubmed: 28199314
Nat Genet. 2013 May;45(5):478-86
pubmed: 23525077
Cancer Res. 2014 Sep 1;74(17):4706-19
pubmed: 25035397
Bioinformatics. 2012 Jun 1;28(11):1530-2
pubmed: 22539670
JAMA Oncol. 2019 Apr 01;5(4):546-550
pubmed: 30570649
Bioinformatics. 2014 May 15;30(10):1363-9
pubmed: 24478339
PLoS One. 2013 Nov 08;8(11):e74380
pubmed: 24250782
Nat Commun. 2017 Nov 3;8(1):1315
pubmed: 29101368
Cancer Res. 2017 Nov 1;77(21):e108-e110
pubmed: 29092952
Genome Biol. 2011;12(4):R41
pubmed: 21527027
J Clin Oncol. 2016 Sep 1;34(25):2980-7
pubmed: 27354485
NPJ Breast Cancer. 2018 Jul 2;4:16
pubmed: 29978035
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
Clin Cancer Res. 2016 Aug 1;22(15):3764-73
pubmed: 26957554
Nat Genet. 2020 Feb;52(2):208-218
pubmed: 32015527
Nat Genet. 2016 Oct;48(10):1131-41
pubmed: 27595477
Curr Protoc Bioinformatics. 2016 Dec 8;56:15.9.1-15.9.17
pubmed: 27930809
Gut. 2012 Mar;61(3):427-38
pubmed: 21930732
J Immunother Cancer. 2017 Feb 21;5:18
pubmed: 28239471
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
Nature. 2017 Nov 23;551(7681):512-516
pubmed: 29132146
Ann Oncol. 2020 Feb;31(2):236-245
pubmed: 31959340
Commun Biol. 2018 Oct 24;1:174
pubmed: 30374464
Nature. 2016 May 02;534(7605):47-54
pubmed: 27135926
Science. 2017 Jan 20;355(6322):
pubmed: 28104840
PLoS One. 2012;7(9):e45835
pubmed: 23049875
Nature. 2014 Jan 23;505(7484):495-501
pubmed: 24390350
Nat Commun. 2018 Jul 30;9(1):2983
pubmed: 30061675
Cancer Discov. 2015 Jul;5(7):704-12
pubmed: 26091828
Oncotarget. 2015 Sep 22;6(28):24978-89
pubmed: 26317795
Cancer Prev Res (Phila). 2014 Jan;7(1):114-27
pubmed: 24253313
Nature. 2020 Feb;578(7793):82-93
pubmed: 32025007
Mol Oncol. 2021 Apr;15(4):901-914
pubmed: 33506581
Nat Rev Genet. 2019 May;20(5):253
pubmed: 30890789
Nat Genet. 2020 Mar;52(3):331-341
pubmed: 32025003
Nat Commun. 2018 Aug 13;9(1):3220
pubmed: 30104673
Cancer Discov. 2019 Aug;9(8):1022-1035
pubmed: 31164343
BMC Med Genomics. 2019 Feb 4;12(1):31
pubmed: 30717762
Cell. 2019 Mar 7;176(6):1282-1294.e20
pubmed: 30849372
BMC Bioinformatics. 2011 Aug 04;12:323
pubmed: 21816040
Cell. 2018 Sep 6;174(6):1586-1598.e12
pubmed: 30100188
Cancer Discov. 2021 May;11(5):1024-1039
pubmed: 33722796
Bioinformatics. 2014 Feb 01;30(3):428-30
pubmed: 24336642
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Genome Biol. 2016 Oct 20;17(1):218
pubmed: 27765066
Lancet Gastroenterol Hepatol. 2020 Jun;5(6):582-597
pubmed: 32246941
Immunity. 2018 Apr 17;48(4):812-830.e14
pubmed: 29628290
Nat Commun. 2014 Oct 29;5:5224
pubmed: 25351503
Sci Rep. 2021 Oct 29;11(1):21304
pubmed: 34716381
Fly (Austin). 2012 Apr-Jun;6(2):80-92
pubmed: 22728672
Cancer Res. 2010 Apr 15;70(8):3052-61
pubmed: 20388795
Nat Genet. 2015 Sep;47(9):1047-55
pubmed: 26192918
Ann Oncol. 2020 Aug;31(8):1011-1020
pubmed: 32387455
Cell Chem Biol. 2018 Jan 18;25(1):36-49
pubmed: 29153851
Nat Commun. 2019 Oct 8;10(1):4571
pubmed: 31594944
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
Immunity. 2013 Oct 17;39(4):782-95
pubmed: 24138885
Nat Genet. 2015 Sep;47(9):1038-1046
pubmed: 26192915
Cancer Res. 2019 Dec 15;79(24):6238-6246
pubmed: 31641033
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
Cancer Immunol Res. 2016 Jan;4(1):41-8
pubmed: 26546451
N Engl J Med. 2021 Apr 1;384(13):1191-1203
pubmed: 33789008
Gastroenterology. 2018 Jan;154(2):390-405
pubmed: 28780073
Stat Med. 2005 Oct 30;24(20):3089-110
pubmed: 16189810
Genome Med. 2016 Jan 29;8(1):11
pubmed: 26825632
J Chromatogr. 1989 Feb 24;487(2):357-63
pubmed: 2723002
Carcinogenesis. 2016 Apr;37(4):356-65
pubmed: 26905591
Nat Genet. 2019 Mar;51(3):506-516
pubmed: 30718927
Nat Immunol. 2013 Oct;14(10):1014-22
pubmed: 24048123
Bioinformatics. 2010 Mar 15;26(6):841-2
pubmed: 20110278
Cell Death Differ. 2021 Jul;28(7):2179-2193
pubmed: 33649470
Genome Biol. 2017 Nov 15;18(1):220
pubmed: 29141660
Cell. 2012 May 25;149(5):994-1007
pubmed: 22608083
Nature. 2017 May 11;545(7653):175-180
pubmed: 28467829
Gastroenterology. 2020 May;158(6):1682-1697.e1
pubmed: 32032585
Genome Biol. 2013 Sep 24;14(9):r105
pubmed: 24063430
Oncogene. 2002 Aug 12;21(35):5361-79
pubmed: 12154399
Cancer Lett. 2019 Feb 1;442:279-286
pubmed: 30419350
Nucleic Acids Res. 2017 Feb 28;45(4):e22
pubmed: 27924034
Nat Med. 2017 Apr;23(4):517-525
pubmed: 28288110
N Engl J Med. 2012 May 31;366(22):2074-84
pubmed: 22646630
Genome Biol. 2016 Jun 16;17(1):128
pubmed: 27311963

Auteurs

Marjan M Naeini (M)

QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.

Felicity Newell (F)

QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.

Lauren G Aoude (LG)

Frazer Institute, The University of Queensland, Woolloongabba, QLD, 4102, Australia.

Vanessa F Bonazzi (VF)

Frazer Institute, The University of Queensland, Woolloongabba, QLD, 4102, Australia.

Kalpana Patel (K)

Frazer Institute, The University of Queensland, Woolloongabba, QLD, 4102, Australia.

Guy Lampe (G)

Princess Alexandra Hospital, Woolloongabba, QLD, 4102, Australia.

Lambros T Koufariotis (LT)

QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.

Vanessa Lakis (V)

QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.

Venkateswar Addala (V)

QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.

Olga Kondrashova (O)

QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.

Rebecca L Johnston (RL)

QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.

Sowmya Sharma (S)

QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.
Faculty of Medicine, University of Queensland, Brisbane, QLD, 4006, Australia.
Anatomical Pathology, Australian Clinical Labs, 2153, Sydney, Australia.

Sandra Brosda (S)

Frazer Institute, The University of Queensland, Woolloongabba, QLD, 4102, Australia.

Oliver Holmes (O)

QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.

Conrad Leonard (C)

QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.

Scott Wood (S)

QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.

Qinying Xu (Q)

QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.

Janine Thomas (J)

Princess Alexandra Hospital, Woolloongabba, QLD, 4102, Australia.
Mater Research Institute, Mater Misericordiae, South Brisbane, QLD, 4101, Australia.

Euan Walpole (E)

Princess Alexandra Hospital, Woolloongabba, QLD, 4102, Australia.

G Tao Mai (G)

Princess Alexandra Hospital, Woolloongabba, QLD, 4102, Australia.

Stephen P Ackland (SP)

Department of Medical Oncology, Calvary Mater Newcastle, Waratah, NSW, 2298, Australia.

Jarad Martin (J)

Department of Radiation Oncology, Calvary Mater Newcastle, Waratah, NSW, 2298, Australia.

Matthew Burge (M)

Royal Brisbane and Women's Hospital, Herston, QLD, 4029, Australia.

Robert Finch (R)

Royal Brisbane and Women's Hospital, Herston, QLD, 4029, Australia.

Christos S Karapetis (CS)

Flinders University Department of Medical Oncology, Flinders Medical Centre, Adelaide, SA, 5042, Australia.

Jenny Shannon (J)

Nepean Cancer Care Centre, Nepean Hospital, Sydney, NSW, 2747, Australia.

Louise Nott (L)

Department of Medical Oncology, Royal Hobart Hospital, Hobart, TAS, Australia.

Robert Bohmer (R)

Department of General Surgery, Royal Hobart Hospital, Hobart, TAS, Australia.

Kate Wilson (K)

NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, 2006, Australia.

Elizabeth Barnes (E)

NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, 2006, Australia.

John R Zalcberg (JR)

Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC, 3004, Australia.

B Mark Smithers (B)

Princess Alexandra Hospital, Woolloongabba, QLD, 4102, Australia.
Faculty of Medicine, University of Queensland, Brisbane, QLD, 4006, Australia.

John Simes (J)

NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, 2006, Australia.

Timothy Price (T)

Medical Oncology Unit, The Queen Elizabeth Hospital and University of Adelaide, Adelaide, SA, 5011, Australia.

Val Gebski (V)

NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, 2006, Australia.

Katia Nones (K)

QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.

David I Watson (DI)

Flinders University Discipline of Surgery, Flinders Medical Centre, Adelaide, SA, 5042, Australia.

John V Pearson (JV)

QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.

Andrew P Barbour (AP)

Frazer Institute, The University of Queensland, Woolloongabba, QLD, 4102, Australia. a.barbour@uq.edu.au.
Princess Alexandra Hospital, Woolloongabba, QLD, 4102, Australia. a.barbour@uq.edu.au.

Nicola Waddell (N)

QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia. nic.waddell@qimrberghofer.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH